Alimera Sciences (NASDAQ:ALIM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on the company. Alliance Global Partners reissued a neutral rating on shares of Alimera Sciences in a report on Tuesday, June 25th. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price objective on the stock. in a research note on Tuesday, June 25th. Finally, Maxim Group restated a hold rating on shares of Alimera Sciences in a research note on Tuesday, June 25th.

Alimera Sciences Stock Performance

Shares of ALIM opened at $5.56 on Friday. The company’s 50 day simple moving average is $5.56 and its 200-day simple moving average is $4.30. Alimera Sciences has a 12-month low of $2.61 and a 12-month high of $5.65. The firm has a market cap of $291.28 million, a PE ratio of -3.54 and a beta of 1.25. The company has a current ratio of 2.79, a quick ratio of 2.62 and a debt-to-equity ratio of 1.80.

Alimera Sciences (NASDAQ:ALIM) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The business had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. As a group, equities analysts predict that Alimera Sciences will post -0.13 EPS for the current year.

Institutional Trading of Alimera Sciences

Several hedge funds have recently modified their holdings of ALIM. Glazer Capital LLC purchased a new position in Alimera Sciences in the second quarter worth $3,067,000. Vanguard Group Inc. lifted its stake in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after purchasing an additional 396,506 shares during the period. Ancora Advisors LLC purchased a new stake in Alimera Sciences during the first quarter worth about $915,000. Deltec Asset Management LLC acquired a new position in Alimera Sciences during the second quarter worth about $690,000. Finally, Gabelli Funds LLC purchased a new position in Alimera Sciences in the second quarter valued at about $600,000. 99.83% of the stock is owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).